No registrations found.
ID
Source
Brief title
Health condition
Parkinson's Disease
Therapy adherence
Medication
Polypharmacy
Sponsors and support
Intervention
Outcome measures
Primary outcome
The primary objective of the study is to assess whether a structured medication review improves medication adherence and leads to better quality of life in patients with PD after a follow-up of three months and six months, compared to patients with PD who will not receive a structured medication review during follow-up. Disease-specific quality of life will be measured, using the Parkinson’s Disease Questionnaire-39 (PDQ-39).
Secondary outcome
The secondary objectives of the study are measurements of activities in daily life and physical disability, mobility and motor symptoms, non-motor symptoms, cost-effectiveness and health state, and personal carers’ quality of life, by comparing the results of PD patients who receive a medication review with PD patients who will not receive a medication review. The effects will be measured by using the AMC Linear Disability Scale (ALDS), the Non Motor Symptoms Questionnaire (NMSQuest), the EuroQOL-5 Dimensions (EQ-5D), the Visual Analogue Scale (VAS), and the PDQ carer questionnaire.
Background summary
The aim of this study is to assess whether a structured medication review in primary care improves medication adherence and leads to positive patient outcomes in patients with PD. The expectation is that the results of this study might be used to improve daily treatment of patients with PD.
Study objective
The expectation is that a structured medication review in primary care improves medication adherence and leads to positive patient outcomes in patients with Parkinson's Disease
Study design
- Baseline
- Three months
- Six months
Intervention
The study is a prospective randomized, controlled trial (RCT).
As intervention, community pharmacists perform a structured medication review as one-time assessment at the start of the study within the intervention group. Measurements at baseline will be done before the intervention. The follow-up measurements will take place after three months and six months.
A structured medication review can be defined as ‘a structured, critical examination of a patient’s medicines with the objective of reaching an agreement with the patient about treatment, optimizing the impact of medicines, minimizing the number of medication-related problems and reducing waste’
P.O. Box 50000
J. Palen, van der
Enschede 7500 KA
The Netherlands
+31 (0)53 4872023
P.O. Box 50000
J. Palen, van der
Enschede 7500 KA
The Netherlands
+31 (0)53 4872023
Inclusion criteria
The patient has/is:
• Diagnosed with PD according to the UK-brain banking criteria
• ≥ Eighteen years of age
• ≥ Four different medications daily
• ≥ Four medication intake moments daily
• Expressing motor symptoms or non-motor symptoms
• Living (semi)-independent in the region of Enschede
• Able to read and write the Dutch language
Exclusion criteria
The patient has/is:
• Unable to administrate own medications, excluding PD patients with personal or family home caregivers
• Received a medication review within a year before the study
Design
Recruitment
Followed up by the following (possibly more current) registration
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
| Register | ID |
|---|---|
| NTR-new | NL4360 |
| NTR-old | NTR4500 |
| CCMO | NL48661.044.14 |
| OMON | NL-OMON44681 |